Association between p53 Expression and Amount of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Most triple-negative breast cancers (TNBCs) have a high histologic grade, are associated with high endoplasmic stress, and possess a high frequency of TP53 mutations. TP53 missense mutations lead to the production of mutant p53 protein and usually show high levels of p53 protein expression. Tumor-infiltrating lymphocytes (TILs) accumulate as part of the anti-tumor immune response and have a strong prognostic and predictive significance in TNBC. We aimed to elucidate the association between p53 expression and the amount of TILs in TNBC. Methods: In 678 TNBC patients, we evaluated TIL levels and expression of endoplasmic stress molecules. Immunohistochemical examination of p53 protein expression was categorized into three groups: no, low, and high expression. Results: No, low, and high p53 expression was identified in 44.1% (n = 299), 20.1% (n = 136), and 35.8% (n = 243) of patients, respectively. Patients with high p53 expression showed high histologic grade (p < .001), high TIL levels (p = .009), and high expression of endoplasmic reticulum stress-associated molecules (p-eIF2a, p = .013; XBP1, p = .007), compared to patients with low p53 expression. There was no significant difference in disease-free (p = .406) or overall survival rates (p = .444) among the three p53 expression groups. Conclusions: High p53 expression is associated with increased expression of endoplasmic reticulum stress molecules and TIL influx.
Abstract
Background: Most triple-negative breast cancers (TNBCs) have a high histologic grade, are associated with high endoplasmic stress, and possess a high frequency of TP53 mutations. TP53 missense mutations lead to the production of mutant p53 protein and usually show high levels of p53 protein expression. Tumor-infiltrating lymphocytes (TILs) accumulate as part of the anti-tumor immune response and have a strong prognostic and predictive significance in TNBC. We aimed to elucidate the association between p53 expression and the amount of TILs in TNBC. Methods: In 678 TNBC patients, we evaluated TIL levels and expression of endoplasmic stress molecules. Immunohistochemical examination of p53 protein expression was categorized into three groups: no, low, and high expression. Results: No, low, and high p53 expression was identified in 44.1% (n = 299), 20.1% (n = 136), and 35.8% (n = 243) of patients, respectively. Patients with high p53 expression showed high histologic grade (p < .001), high TIL levels (p = .009), and high expression of endoplasmic reticulum stress-associated molecules (p-eIF2a, p = .013; XBP1, p = .007), compared to patients with low p53 expression. There was no significant difference in disease-free (p = .406) or overall survival rates (p = .444) among the three p53 expression groups. Conclusions: High p53 expression is associated with increased expression of endoplasmic reticulum stress molecules and TIL influx.
참고문헌 (33)
- Yamashita N, "Picrasidine G decreases viability of MDA-MB 468 EGFR-overexpressing triple-negative breast cancer cells through inhibition of EGFR", STAT3 signaling pathway, 2017, pp.27, 2608~2612
- Yadav BS, "Biomarkers in triple negative breast cancer : a review", World J Clin Oncol, 6, pp.252~263 (2015)
- van Rooijen JM, "Immunotherapeutic options on the horizon in breast cancer treatment", Pharmacol Ther, 156, pp.90~101 (2015)
- Kim JY, "Activation of the PERK-eIF2alpha pathway is associated with tumor-infiltrating lymphocytes in HER2-positive breast cancer", Anticancer Res, 36, pp.2705~2711 (2016)
- Kim YA, "MxA expression is associated with tumor-infiltrating lymphocytes and is a prognostic factor in triplenegative breast cancer", Breast Cancer Res Treat, 156, pp.597~606 (2016)
- Lee HJ, "Tertiary lymphoid structures : prognostic significance and relationship with tumour-infiltrating lymphocytes in triple-negative breast cancer", J Clin Pathol, 69, pp.422~430 (2016)
- Lee HJ, "Differential expression of major histocompatibility complex class I in subtypes of breast cancer is associated with estrogen receptor and interferon signaling", Oncotarget, 7, pp.30119~30132 (2016)
- Park IA, "Endoplasmic reticulum stress induces secretion of high-mobility group proteins and is associated with tumor-infiltrating lymphocytes in triple-negative breast cancer", Oncotarget, 7, pp.59957~59964 (2016)
- Chen X, "XBP1 promotes triple-negative breast cancer by controlling the HIF1alpha pathway", Nature, 508, pp.103~107 (2014)
- Chang-chang Han, "New Insights into the Role of Endoplasmic Reticulum Stress in Breast Cancer Metastasis", Journal of Breast Cancer, 21(4), pp.354~362 (2018), 한국유방암학회[DOI]
- Oros Klein K, "Gene coexpression analyses differentiate networks associated with diverse cancers harboring TP53 missense or null mutations", Front Genet, 7, pp.137~ (2016)
- Kandioler-Eckersberger D, "TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients", Clin Cancer Res, 6, pp.50~56 (2000)
- Brosh R, "When mutants gain new powers : news from the mutant p53 field", Nat Rev Cancer, 9, pp.701~713 (2009)
- Freed-Pastor WA, "Mutant p53 : one name, many proteins", Genes Dev, 26, pp.1268~1286 (2012)
- Muller PA, "p53 mutations in cancer", Nat Cell Biol, 15, pp.2~8 (2013)
- Yue X, "Mutant p53 in cancer : accumulation, gain-of-function, and therapy", J Mol Biol, 429, pp.1595~1606 (2017)
- Alsner J, "Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients", Clin Cancer Res, 6, pp.3923~3931 (2000)
- Jin MS, "New insight on the biological role of p53 protein as a tumor suppressor : re-evaluation of its clinical significance in triple-negative breast cancer", Tumour Biol, 37, pp.11017~11024 (2016)
- Cancer Genome Atlas Network, "Comprehensive molecular portraits of human breast tumours", Nature, 490, pp.61~70 (2012)
- Duffy MJ, "p53 as a target for the treatment of cancer", Cancer Treat Rev, 40, pp.1153~1160 (2014)
- Duffy MJ, "Mutant p53 as a target for cancer treatment", Eur J Cancer, 83, pp.258~265 (2017)
- Kojima YA, "Reproducible evaluation of tumor-infiltrating lymphocytes(TILs)using the recommendations of International TILs Working Group 2014", Ann Diagn Pathol, 35, pp.77~79 (2018)
- Park IA, "Expression of the MHC class II in triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and interferon signaling", PLoS One, 12, pp.e0182786~ (2017)
- Adams S, "Tumor infiltrating lymphocytes(TILs)improve prognosis in patients with triple negative breast cancer(TNBC)", Oncoimmunology, 4, pp.e985930~ (2015)
- Lee HJ, "Cytoplasmic expression of high mobility group B1(HMGB1)is associated with tumor-infiltrating lymphocytes(TILs)in breast cancer", Pathol Int, 66, pp.202~209 (2016)
- Darb-Esfahani S, "Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline", taxane-based chemotherapy, 2016, pp.7, 67686~67698
- Maeda T, "Immunohistochemical co-expression status of cytokeratin 5", 6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer, 2016, pp.49, 11~21
- Wu M, "Expression of SIRT1 is associated with lymph node metastasis and poor prognosis in both operable triplenegative and non-triple-negative breast cancer", Med Oncol, 29, pp.3240~3249 (2012)
- Zhang J, "An associated classification of triple negative breast cancer : the risk of relapse and the response to chemotherapy", Int J Clin Exp Pathol, 6, pp.1380~1391 (2013)
- Biganzoli E, "p53 status identifies two subgroups of triple-negative breast cancers with distinct biological features", Jpn J Clin Oncol, 41, pp.172~179 (2011)
- Kashiwagi S, "Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II : usefulness of prognostic markers E-cadherin and Ki67", Breast Cancer Res, 13, pp.R122~ (2011)
- Wang J, "ERbeta1 inversely correlates with PTEN", PI3K, Breast Cancer Res Treat, pp.2015, 152[DOI]
- Lheureux S, "Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician", Eur J Nucl Med Mol Imaging, 44(Suppl 1), pp.41~54 (2017)